The Treatment Dilemma of Arteriopathy in Takayasu Arteritis- A State-of-the-Art Approach

Firouzi, Ata; Khalilipur, Ehsan; Khajali, Zahra; Pouraliakbar, Hamidreza; Baay, Mohammadreza; Abdi, Amir; Panah, Mohammad Karimi; Zadeh, Leila Shokrian; Kiani, Keivan; Rezaeian, Aryan; Hosseini, Zahra

doi:10.1016/j.cpcardiol.2022.101359

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[23] имеют высокую (94%) чувствительность, однако их специфичность еще предстоит оценить [24,25]. Традиционная концепция трехфазного заболевания при АТ (конституциональные нарушения, за которыми следует фаза воспаления сосудов, а затем -фаза стеноза) в настоящее время поставлена под сомнение [6,24,25].…”

unclassified

“…Тоцилизумаб (ТЦЗ), гуманизированное моноклональное антитело, блокирующее передачу сигналов ИЛ6 (см. таблицу), был одобрен для лечения гигантоклеточного артериита [6,29,30]. Впервые о клинической эффективности ТЦЗ при АТ сообщалось в 2008 г.…”

unclassified

See 1 more Smart Citation

Modern approaches to the treatment of Takayasu arteritis

Egorova,

Tarasova,

Koylubaeva

et al. 2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Takayasu arteritis (AT) is a chronic granulomatous systemic vasculitis that affects large vessels and requires a multidisciplinary approach as the clinical signs are non-specific and disease activity is difficult to assess. Early rational drug treatment of AT suppresses both vascular and systemic inflammation, with glucocorticoids and immunosuppressants being of paramount importance. Advances in the understanding of the pathophysiology of AT have contributed to the development of new treatments that target key pro-inflammatory factors and involve the use of biologic disease-modifying antirheumatic drugs.

show abstract

unclassified